Bicalutamide
Androgen Receptor Antagonist
DB01128
Approved Indication
For treatment (together with surgery or LHRH analogue) of advanced prostatic cancer.
1
Targets
0
Resistance Mutations
0
References
3D Structure
No structure available
No co-crystal structure available
Protein Targets
Mechanism of Action
Bicalutamide competes with androgen for the binding of androgen receptors, consequently blocking the action of androgens of adrenal and testicular origin which stimulate the growth of normal and malignant prostatic tissue.
Details
DrugBank ID
DB01128 ↗
Approval Date
1995-10-16
Molecular Weight
430.373 g/mol
Drug Class
Androgen Receptor Antagonist
ATC Codes
L02BB03
Synonyms
Bicalutamida, Bicalutamide, Bicalutamidum
PubChem
CID: 2375 ↗
ChEMBL
CHEMBL409 ↗
SMILES
CC(O)(CS(=O)(=O)C1=CC=C(F)C=C1)C(=O)NC1=CC(=C(C=C1)C#N)C(F)(F)F
ADMET Profile
Computing properties…